Proprietary precision HLA redirecting engagers designed to bring T cells into close contact with tumor cells to trigger tumor cell destruction.

A first-in-class bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01 for treatment of p53 mutant cancers.